Alpha Cognition, Inc.’s Lock-Up Period To Expire on May 12th (NASDAQ:ACOG)

Alpha Cognition’s (NASDAQ:ACOG) lock-up period is set to expire on Monday, May 12th. Alpha Cognition had issued 8,695,653 shares in its IPO on November 12th. The total size of the offering was $50,000,005 based on an initial share price of $5.75. After the expiration of Alpha Cognition’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Analyst Ratings Changes

ACOG has been the subject of several research reports. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Alpha Cognition in a research note on Monday, March 31st. Raymond James raised shares of Alpha Cognition to a “moderate buy” rating in a research note on Tuesday, March 25th.

Alpha Cognition Stock Down 1.2 %

ACOG opened at $7.40 on Friday. The stock’s fifty day simple moving average is $5.22. The firm has a market cap of $118.55 million, a price-to-earnings ratio of -2.89 and a beta of 2.48. Alpha Cognition has a 52 week low of $3.75 and a 52 week high of $8.61.

Alpha Cognition (NASDAQ:ACOG) last released its quarterly earnings data on Monday, March 31st. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.03).

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Boothbay Fund Management LLC bought a new position in shares of Alpha Cognition during the fourth quarter worth $1,284,000. Rosalind Advisors Inc. acquired a new stake in Alpha Cognition during the 4th quarter worth $1,489,000. Bleichroeder LP acquired a new position in Alpha Cognition in the fourth quarter valued at about $1,024,000. Aristides Capital LLC acquired a new position in Alpha Cognition in the fourth quarter valued at about $1,178,000. Finally, Altium Capital Management LLC bought a new stake in shares of Alpha Cognition in the fourth quarter worth about $1,620,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.